动脉高血压-临床试验更新 2023 年
Felix Götzinger1, Michael Kunz2, Lucas Lauder2
1From the Department of Internal Medicine III, Cardiology, Angiology and Intensive Care Medicine, University Hospital Saarland, 66424, Homburg, Germany. felix.goetzinger@uks.eu.
概括
本综述强调了2022-2023年高血压试验的关键发现,包括抗性高血压的新疗法和最佳药物治疗时间. 它解决了血压目标和基于新型设备的疗法,以获得更好的心血管结果.
科学领域:
- 心脏病学 心脏病学
- 腎臟病學 (nephrology) 是一種醫學.
- 药理学 药理学是指药理学的学科.
背景情况:
- 动脉高血压显著增加心血管疾病和死亡率.
- 高血压研究是一个充满活力和不断发展的领域.
- 有效的管理策略对于患者的治疗结果至关重要.
研究的目的:
- 从2022年到2023年初,总结高血压研究中的关键临床试验.
- 介绍关于药理和基于设备的治疗方法的新发现.
- 讨论最佳血压目标和治疗惯性.
主要方法:
- 审查2022年和2023年初发表的主要临床试验.
- 对药理干预措施的数据分析,包括耐药高血压.
- 包括有关怀孕相关高血压和中风后血压管理的研究.
主要成果:
- 对抗性高血压的新药学方法显示出有希望.
- 进一步阐明了服用抗高血压药物的最佳时间.
- 新型基于设备的疗法正在成为治疗选择.
- 在血压管理方面,指导惯性仍然是一个挑战.
结论:
- 最近的试验在高血压管理方面取得了重大进展.
- 优化治疗目标和解决惯性至关重要.
- 新兴疗法,包括基于设备的干预措施,扩大了治疗的可能性.
相关概念视频
Hypertension III: Clinical Manifestations and Diagnostic Studies
27
Hypertension is asymptomatic and also referred to as the "silent killer" until it progresses to a severe stage or causes target organ disease. Patients may experience symptoms stemming from the strain on blood vessels and tissues in various organs or the heart's increased workload.Physical exams might show no abnormalities other than high blood pressure. Signs of vascular damage, when present, correspond to the organs supplied by the affected vessels, leading to target organ damage. For...
27
Hypertension IV: Drug Therapy and Lifestyle Modifications
17
Multiple classes of antihypertensive medications are employed in treating hypertension. The most commonly recommended first-line treatments include:Thiazide Diuretics, such as chlorthalidone, increase sodium and water excretion from the body, reducing blood volume and blood pressure.Angiotensin-converting enzyme inhibitors, like lisinopril, block the conversion of angiotensin I to II, a potent vasoconstrictor lowering blood pressure.Angiotensin II Receptor Blockers (ARBs) prevent angiotensin II...
17
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
209
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
209
Hypertension II: Pathophysiology
20
Hypertension is a chronic condition in which the blood's force against artery walls is excessively high, posing risks such as heart disease. The condition's underlying mechanisms involve complex interactions among the cardiovascular, kidney, and autonomic nervous systems.Renin-Angiotensin-Aldosterone System (RAAS): This system significantly influences blood pressure regulation. When blood pressure decreases, the kidneys secrete renin. This enzyme transforms angiotensinogen, a plasma protein,...
20
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
202
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
202
Atherosclerosis III: Management
13
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
13


